<DOC>
	<DOCNO>NCT00671294</DOCNO>
	<brief_summary>This purpose study assess efficacy safety Ramelteon , daily ( QD ) , elderly subject chronic insomnia .</brief_summary>
	<brief_title>Safety Efficacy Ramelteon Elderly Subjects With Chronic Insomnia .</brief_title>
	<detailed_description>Insomnia characterize complaint difficulty initiate maintain sleep nonrestorative non-refreshing sleep . Transient insomnia affect approximately one-third one-half US population , base result 2 survey representative sample adult US population conduct Gallup Organization respondent ask .ever difficulty sleep . Based report regular frequent sleep difficulty , result study suggest approximately one-tenth US population experience chronic insomnia . The ideal treatment insomnia would reduce latency onset sleep increase total sleep time , without negative impact sleep architecture without safety concern next-day effect . Ramelteon melatonin-1 receptor agonist global development Takeda Chemical Industries , Ltd. , Osaka , Japan , treatment transient chronic insomnia treatment Circadian Rhythm Sleep Disorders . Participation study anticipate 2 month .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Male postmenopausal female . Primary insomnia define Diagnostic Statistical Manual Mental Disorders , Text Revision least 3 month define subjective sleep latency great equal 30 minute , subjective total sleep time le equal 6.5 hour per night , daytime complaint ( ) associate disturbed sleep . Mean latency great equal 20 minute per polysomnography two consecutive screen night neither night le 15 minute . Also , mean 60 minute wake time 480 minute bed across two night night le 45 minute . Habitual bedtime 8:30 p.m. 12:00 a.m . Body mass index 18 34 , inclusive . Exclusion Criteria Known hypersensitivity Ramelteon related compound , include melatonin . Previously participate study involve Ramelteon . Participated investigational study and/or take investigational drug within 30 day five halflives prior Day 1 singleblind study medication , whichever longer . Sleep schedule change require employment ( eg , shift worker ) within three month prior Day 1 singleblind study medication , fly across great three time zone within seven day prior screen . Participated weight loss program substantially alter exercise routine within 30 day prior Day 1 singleblind study medication . Ever history seizure , sleep apnea , chronic obstructive pulmonary disease , schizophrenia , bipolar disorder , mental retardation , cognitive disorder . History psychiatric disorder ( include anxiety depression ) within past 12 month . History drug addiction drug abuse within past 12 month . History alcohol abuse within past 12 month . Had acute clinically significant illness , determine investigator , within 30 day prior Day 1 singleblind study medication . Current significant neurological ( include cognitive psychiatric disorder ) , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematologic , metabolic disease , unless currently control stable protocolallowed medication 30 day prior Day 1 singleblind study medication . Used tobacco product within 90 day prior Day 1 singleblind study medication . Used melatonin , drug supplement know affect sleep/wake function , consume grapefruit grapefruit juice within 5 day ( 5 half life , whichever long ) prior Day 1 singleblind study medication . Used central nervous system medication within 3 week ( 5 half life drug , whichever long ) prior Day 1 singleblind study medication . These medication must use treat psychiatric disorder . Any clinically important abnormal finding determine medical history , physical examination , electrocardiogram , clinical laboratory test , determine investigator . Positive hepatitis panel include antihepatitis A virus ( immunoglobulin M exclusionary ) , anti hepatitis B surface ( except subject receive hepatitis B virus vaccination ) , hepatitis B surface antigen , anti hepatitis B core ( immunoglobulin M exclusionary ) , antihepatitis C virus . Positive urine drug screen include alcohol screening checkin positive breathalyzer test checkin . Apnea hypopnea index ( per hour sleep ) great 15 see polysonography , first night polysonography screening . Periodic leg movement arousal index ( per hour sleep ) great 20 see polysonography , first night polysonography screen . Any additional condition ( ) Investigator.s opinion would : ) affect sleep/wake function , b ) prohibit subject completing study , c ) best interest subject participate study . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Within 3 week prior Day 1 singleblind study medication study : anxiolytic hypnotic antidepressant anticonvulsant sedate H1 antihistamine systemic steroid respiratory stimulant ( eg , theophylline ) decongestants overthe counter prescription stimulant overthe counter prescription diet aids central nervous system active drug ( include herbal preparation central nervous system effect ) narcotic analgesic beta blocker St. John.s wort kavakava gingko biloba , supplement Within 5 day prior Day 1 singleblind study medication study : melatonin , drug supplement know affect sleep/wake function .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Insomnia</keyword>
</DOC>